Longboard Pharmaceuticals Stock Net Asset
| LBPH Stock | USD 59.98 0.00 0.00% |
Longboard Pharmaceuticals fundamentals help investors to digest information that contributes to Longboard Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Longboard Stock. The fundamental analysis module provides a way to measure Longboard Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Longboard Pharmaceuticals stock.
Longboard | Net Asset |
Longboard Pharmaceuticals Company Net Asset Analysis
Longboard Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Longboard Pharmaceuticals Net Asset | 50.7 M |
Most of Longboard Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Longboard Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Longboard Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Longboard Pharmaceuticals is extremely important. It helps to project a fair market value of Longboard Stock properly, considering its historical fundamentals such as Net Asset. Since Longboard Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Longboard Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Longboard Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Longboard Total Assets
Total Assets |
|
Based on the recorded statements, Longboard Pharmaceuticals has a Net Asset of 50.7 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Longboard Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Longboard Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Longboard Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Longboard Pharmaceuticals by comparing valuation metrics of similar companies.Longboard Pharmaceuticals is currently under evaluation in net asset category among its peers.
Longboard Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Longboard Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Longboard Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Longboard Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Longboard Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Longboard Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Longboard Pharmaceuticals' value.| Shares | Woodline Partners Lp | 2024-09-30 | 1 M | Pictet Asset Manangement Sa | 2024-09-30 | 918.6 K | Jennison Associates Llc | 2024-09-30 | 917.5 K | State Street Corp | 2024-09-30 | 855.8 K | Geode Capital Management, Llc | 2024-09-30 | 746.1 K | Driehaus Capital Management Llc | 2024-09-30 | 729.5 K | Emerald Advisers, Llc | 2024-09-30 | 683.6 K | Lord, Abbett & Co Llc | 2024-09-30 | 626.9 K | American Century Companies Inc | 2024-09-30 | 569.7 K | Fmr Inc | 2024-09-30 | 4.4 M | Farallon Capital Management, L.l.c. | 2024-09-30 | 3.2 M |
Longboard Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 2.06 B | ||||
| Shares Outstanding | 34.44 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 98.81 % | ||||
| Number Of Shares Shorted | 1.93 M | ||||
| Price To Book | 8.51 X | ||||
| EBITDA | (56.75 M) | ||||
| Net Income | (54.42 M) | ||||
| Cash And Equivalents | 87.42 M | ||||
| Cash Per Share | 5.09 X | ||||
| Total Debt | 475 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 11.95 X | ||||
| Book Value Per Share | 7.05 X | ||||
| Cash Flow From Operations | (50.87 M) | ||||
| Short Ratio | 1.27 X | ||||
| Earnings Per Share | (2.25) X | ||||
| Target Price | 64.0 | ||||
| Number Of Employees | 50 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 2.34 B | ||||
| Total Asset | 50.7 M | ||||
| Retained Earnings | (140.56 M) | ||||
| Working Capital | 40.45 M | ||||
| Net Asset | 50.7 M |
About Longboard Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Longboard Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Longboard Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Longboard Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Longboard Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Longboard Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Longboard Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Longboard Pharmaceuticals Stock:Check out Longboard Pharmaceuticals Piotroski F Score and Longboard Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Longboard Stock please use our How to Invest in Longboard Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Longboard Pharmaceuticals. If investors know Longboard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Longboard Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Return On Assets (0.31) | Return On Equity (0.47) |
The market value of Longboard Pharmaceuticals is measured differently than its book value, which is the value of Longboard that is recorded on the company's balance sheet. Investors also form their own opinion of Longboard Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Longboard Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Longboard Pharmaceuticals' market value can be influenced by many factors that don't directly affect Longboard Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Longboard Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Longboard Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Longboard Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.